NCT04420585

Desmopressin for Bedwetting in Children With SCD

Desmopressin as a Therapy for Nocturnal Enuresis in Pediatric Patients With Sickle Cell Disease

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Montefiore Medical Center · Academic / Other
• Sex: All
• Age: 8 Years – 21 Years
• Healthy volunteers: Not accepted

Summary

This study assesses if using the medication desmopressin will decrease nightime bedwetting in children with sickle cell disease.

Detailed description

Night time bedwetting is a common complication of sickle cell disease, and affects up to 30 % of children. Desmopressin is an oral medication that increases water reabsorption in the kidneys. Studies have shown that it is effective in decreasing bedwetting episodes in children without sickle cell disease. Chronic sickling episodes causing damage to the kidneys could cause permanent damage and may make this treatment ineffective in sickle cell disease. This trial will inform pediatric sickle cell doctors if desmopressin is an appropriate treatment for bed wetting in the investigators patients. This study expanded upon a previously terminated study which had separately registered (NCT02636387, ID: 2014-3768).

Conditions

• Nocturnal Enuresis
• Anemia, Sickle Cell

Interventions

Type	Name	Description
DRUG	Desmopressin	Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement

Timeline

• Start date: 2020-07-07
• Primary completion: 2023-06-12
• Completion: 2023-06-12
• First posted: 2020-06-09
• Last updated: 2024-05-07
• Results posted: 2024-05-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study